Grace Therapeutics, Inc.
NASDAQ Global MarketTotal Valuation
Grace Therapeutics, Inc. carries a market capitalization of 32.12M, placing it among publicly traded companies globally. Its enterprise value stands at 23.19M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 32.12M |
| Enterprise Value | 23.19M |
Share Statistics
Grace Therapeutics, Inc. currently has 16.27M shares outstanding.
| Shares Outstanding | 16.27M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
| PE Ratio | N/A |
| PS Ratio | N/A |
| PB Ratio | 0.77 |
| P/TBV Ratio | 2.96 |
| P/FCF Ratio | -3.69 |
| P/OCF Ratio | -3.69 |
Financial Position
Grace Therapeutics, Inc. maintains a current ratio of 11.47, meaning it holds 11.5x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 11.47 |
| Quick Ratio | 11.02 |
| Debt / Equity | N/A |
| Debt / EBITDA | N/A |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | -36.19 |
| Return on Assets (ROA) | -33.74 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Taxes
| Income Tax | -1.70M |
| Effective Tax Rate | N/A |
Stock Price Statistics
Grace Therapeutics, Inc.'s stock has declined approximately -38.69565% over the past 52 weeks. The 50-day moving average sits at 2.11, while the 200-day moving average is 2.90.
| Beta (5Y) | N/A |
| 52-Week Price Change | -38.69565% |
| 50-Day Moving Average | 2.11 |
| 200-Day Moving Average | 2.90 |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached -10.36M, while operating income came in at -10.37M.
| Revenue | N/A |
| Gross Profit | N/A |
| Operating Income | -10.37M |
| Pretax Income | -21.92M |
| Net Income | -20.22M |
| EBITDA | -10.36M |
| EBIT | -10.37M |
| Earnings Per Share (EPS) | -1.21 |
Balance Sheet
Total book value stands at 48.21M, with working capital of 13.08M providing operational flexibility.
| Cash & Cash Equivalents | 13.76M |
| Total Debt | N/A |
| Net Debt | -13.76M |
| Equity (Book Value) | 48.21M |
| Book Value Per Share | 2.96 |
| Working Capital | 13.08M |
Cash Flow
Grace Therapeutics, Inc. produced -10.29M in operating cash flow over the past twelve months.
| Operating Cash Flow | -10.29M |
| Capital Expenditures | N/A |
| Free Cash Flow | -10.29M |
| FCF Per Share | -0.62 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -10.94 |
| FCF Yield | -27.13 |
Stock Splits
Grace Therapeutics, Inc.'s most recent stock split took place on July 10, 2023 with a 6:1 split ratio.
| Last Split Date | 7/10/2023 |
| Split Ratio | 6:1 |
Scores
Grace Therapeutics, Inc. posts an Altman Z-Score of -13.24, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -13.24 |